Purchase this article with an account.
L. Bonavia, S. De Angelis, C. Rosina, G. Staurenghi; The Length of the New Vessels Regression in Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):282.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the follow-up of retinal and/or disc neovascularization regression in Proliferative Diabetic Retinopathy (PDR) after intravitreal bevacizum
Retrospective chart review of six eyes of six patients with retinal and/or disc neovascularitation secondary to diabetes mellitus. Patients received intravitreal bevacizumab (1.25 mg). Ophthalmic evaluations included nonstandardized Snellen visual acuity (VA), complete ophthalmic examination and fluorescein angiography every month.
At 1 month post injection all patients showed a complete neovascularization regression . At 3 months post injection the new-vessels reapper in 3 of 6 (50%) eyes, at 4 months post injection in 1of 6 eyes (1,66%), at 5 months post injection in 1 of 6 eyes (1,66%) and at 7 months post injection in 1of 6 eyes.
The results suggest that intravitreal bevacizumab is well tolerated and associated with a rapid regression of retinal neovascularization secondary to PDR. Unfortunately the regression is not permanent and the neovascularitation come back (exactly in the same place) after 3-7 months (mean: 5.5).
This PDF is available to Subscribers Only